With the aim of protecting more and more Greek patients, a new product in Cardiovascular Medicine is launched. KERENDIA is now available for patients with CKD & Type 2 Diabetes. Welcome to Bayer Hellas internal Kerendia launch event, focusing on educating & preparing the Sales Team for a successful product promotion in the Greek market. In this event, you familiarized yourselves with the promotional materials & the role plays. This is the first POAP related to a pharmaceutical product. If you received this POAP, you are a True Pioneer in the Web3 space. Bayer is proudly promoting innovative practices. https://www.bayer.com/en/poap-tc

I am a "Senior Insight Solutions Lead" which means that I work in DAIS team and try to generate novel insights for our R&D (and beyond) organization

ChemogenomicsDB (CGDB) and Älixir are prime examples of creating data assets and insight solutions to help improve digital and data capabilities, enhance scientific productivity, and invigorate early pipeline. Using our products, Bayer R&D colleagues can - access to a broad range of data assets essential for solving key drug discovery questions - explore integrated biomedical and chemical data for scientific curiosity, inspiration, and knowledge discovery - generate insights with the assistance of interactive visualizations for evidence-informed decision making